Morepen Labs lands record Rs. 825 crore global CDMO contract

This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major

Lupin receives European Commission approval for biosimilar Ranibizumab

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential

Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator

Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations

Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill

The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats

Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria

The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options

BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research

The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies